Asset Management One Co. Ltd. Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Asset Management One Co. Ltd. raised its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 243,375 shares of the medical device company's stock after acquiring an additional 7,901 shares during the period. Asset Management One Co. Ltd. owned about 0.06% of DexCom worth $19,528,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of DXCM. MFG Wealth Management Inc. acquired a new stake in DexCom during the fourth quarter valued at approximately $1,574,000. Van ECK Associates Corp increased its holdings in shares of DexCom by 325.0% in the fourth quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company's stock valued at $6,674,000 after purchasing an additional 65,622 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in DexCom by 28.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company's stock valued at $4,596,000 after buying an additional 13,111 shares during the last quarter. Peterson Wealth Services increased its stake in shares of DexCom by 7.1% in the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company's stock valued at $236,000 after buying an additional 201 shares during the period. Finally, Essex Financial Services Inc. raised its position in shares of DexCom by 3.3% during the fourth quarter. Essex Financial Services Inc. now owns 9,617 shares of the medical device company's stock worth $748,000 after acquiring an additional 303 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DexCom stock traded down $0.85 during trading on Wednesday, reaching $89.68. The company's stock had a trading volume of 3,037,089 shares, compared to its average volume of 3,632,174. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business's 50-day moving average price is $82.65 and its 200-day moving average price is $75.62. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm has a market cap of $35.03 billion, a PE ratio of 62.71, a P/E/G ratio of 2.31 and a beta of 1.14.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts forecast that DexCom, Inc. will post 1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DXCM. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $99.06.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock valued at $3,309,794 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.